+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


From Illicit To Legal And Beyond To Pharmaceuticals - Global Markets, Competitors And Opportunities: 2015-2020 Analysis And Forecasts

  • ID: 3108312
  • Report
  • February 2015
  • Region: Global
  • 161 Pages
  • Amadee & Company, Inc
1 of 3
Over $100 million in investment dollars have flowed into the Canadian medical marijuana industry already.


  • Aphria Inc
  • Bedrocan Cannabis Corp.
  • Cannabis Science, Inc.
  • GW Pharmaceuticals plc
  • Mettrum Health Corp
  • OrganiGram Holdings Inc.
  • MORE
The objective of this report is to provide a detailed analysis of the global market for Medical Marijuana. It is also to provide a comprehensive analysis of the leading companies producing these products, as well as the competitive environment they operate in. Marijuana (cannabis) remains a controversial drug in the twenty-first century. However, the potential role of specific cannabinoids for medical benefits will be revealed as the twenty-first century matures.

Marijuana is the most widely cultivated illicit drug plant worldwide. The international legal framework on drug control is provided by three United Nations Conventions, which instruct countries to limit drug supply and use to medical and scientific purposes. Nevertheless, there continues to be increasing debate over decriminalization, or even legalization of cannabis in particular.

This report provides an estimate of global cannabis production both in volume and value during the 2015-2020 period. The illicit use of marijuana dwarfs the medical use and that probably always will be the case. But to put global cannabis production in perspective, it is bigger than retail sales of all OTC (over-the-counter) analgesic pharmaceuticals by a factor of 9 and sales of pain medication pharmaceuticals by a factor of 25.

Twenty-three U.S. states and the District of Columbia now have legalized medical marijuana, and two states (Colorado and Washington state) allow for adult use (commonly referred to as recreational use). However, the focus in this report is on the Canada medical marijuana market, which is a new, emerging growth industry. The medical marijuana space in Canada, which went into effect in April 2014, has created conditions for a new highly regulated commercial industry with a limited amount of suppliers vetted extensively by Health Canada. Over $100 million in investment dollars have flowed into the Canadian medical marijuana industry already.

The future of medical marijuana lies in pharmaceutical products for the management of neuropathic pain, hypertension, post-stroke neuroprotection, multiple sclerosis, epilepsy, cancer, and other disorders.

Note: Product cover images may vary from those shown
2 of 3


  • Aphria Inc
  • Bedrocan Cannabis Corp.
  • Cannabis Science, Inc.
  • GW Pharmaceuticals plc
  • Mettrum Health Corp
  • OrganiGram Holdings Inc.
  • MORE
1. Executive Summary

2. Introduction
- Report Objectives
- Methodology and Sources
- Statistical Notes

3. Medical Marijuana
- Introduction
- Used for Thousands of Years
- Cannabis Sativa Plant
- Prevalence of Use
- Method of Consumption
- Cannabis Use with Other Drugs
- Cannabinoids
- Endocannabinoid System
- Benefits of Medical Marijuana
- Medical Adverse Effects
- Dental Effects of Cannabis
- Pulmonary Effects
- Cannabis and Cancer
- Cardiovascular Effects
- Psychiatric Adverse Effects
- Cannabis and Neurodevelopment Effects
- Cannabis and ADHD
- Cannabis Dependence
- Cannabis Withdrawal Syndrome
- Addiction
- Cannabis and Psychosis

4. Global Cannabis Market
- Most Widely Cultivated Illicit Drug Plant
- Indica vs. Sativa
- THC vs. CBD
- Main Cannabis Products
- Legal Issues
- Netherlands Laws
- United States Laws
- Uruguay Laws
- Production and Yields Highly Variable
- Production Estimation Issues
- UNDOC Estimates
- Global Cannabis Production
- Global Cannabis Production by Region
- North America Cannabis Production
- Marijuana Market vs. OTC Analgesic and Pain Pharmaceuticals Markets
- Canada Marijuana Market vs. U.S. Market
- Legalization and Decriminalization
- California Medical Marijuana Market
- Canadian Market Structure More Favorable for Producers
- Illicit Marijuana Production vs. Medical Marijuana Production
- Colorado Black Market for Marijuana

5. Canada Medical Marijuana Market
- New Emerging Growth Industry
- Modern History of Medical Marijuana in Canada
- MMAR vs. MMPR - Regulatory Overhaul Following Safety Concerns and Abuse
- Why MMAR Was Overhauled
- Objectives of MMPR
- Marihuana for Medical Purposes Regulations – The New System
- Injunction Explained
- Patient Application Streamlined
- Prescription Process Under MMPR
- Shipping/Packaging Requirements
- Licensing Process Under MMPR
- Growing Enrollment Numbers Points to Strong Growth
- Health Canada Projected Demand
- How HC Made Its Forecasts Is Somewhat Unknown
- Canada Forecast Patient Growth
- U.S. Forecast Patient Growth
- Growth Rates from A Low Base.
- Market in 2024
- Proposed Expansion Plans of LPs May Satisfy Demand
- More than C$100 Million Invested
- Product Pricing Varies by LP
- Compassionate Pricing Is Not Mandatory
- Licensed Producers
- Good To Be an LP
- Physician Role Is Very Important
- Physician Role Should Not Be Overstated
- MMAR Physician Authorizations
- Physician Penetration Under MMPR
- Health Canada View on Medical Marijuana
- College of Family Physicians of Canada Prescribing Guidelines
- Patients Using Medical Marijuana in Canada by Ailment
- Soils vs. Hydroponic
- Indoor vs. Outdoor
- Production Cycle
- Cost of Production
- Infused Products Not Allowed Yet
- Industry Catalysts
- Consolidation More Likely Than Acquisition
- Edibles Legalization
- Edibles Issues
- Insurance Coverage
- Recreational Legalization
- Potential Risks
- Legislation Changes
- Enterprise Valuations
- Adoption Rates Still Uncertain
- Product Quality and Public Perception

6. Company Profiles

- Aphria Inc (Company Overview, Medical Marijuana)

- Bedrocan Cannabis Corp. (Company Overview, Strategy, Medical Marijuana, Competitive Advantages, Bedrocan BV, Advantages to Bedrocan BV Partnership, License Agreement Lowers Risk, License Agreement Provides Upside, South American Countries Looking to Legalize, Bedrocan Product Suite, Bedrocan, Bedropuur, Bedica, Bediol, Small Product Suite, CFPC Preliminary Guidelines, Facilities, Import Facility, Domestic Production Facility, Acquisition for Facility Growth, BV Import Schedule, State of the Art Growing Operations, Production Flow, Production Ramp, Annual Sales Volume, Cost Per Gram, Marketing Strategy, Retail Prices, Patient Sign up Process, Current Patient Composition, Wait List, Patient Count Growing, Patient Consumption Rates, Physician Outreach and Medical Advisory Board, ISO-9000 Certified, Standardization Advantages, Management and Directors Bring Relationships, Experience, Private Placement, Enterprise Value, Financials)

- Cannabis Science, Inc. (Company Overview, Medical Marijuana, Key Indications, Key Target-Based Actions, Key Technologies, Drugs, CT-1, CS-TATI-1, Cannabinoid Compounds, Facilities, Collaborations, Acquisitions and Spin-Offs, Licensing Agreements, R&D, Financials)

- GW Pharmaceuticals plc (Company Overview, Medical Marijuana, Sativex Multiple Sclerosis Market, Sativex Cancer Pain Market, Epilepsy, Epidiolex Market, Inflammatory Bowel Disease, Marijuana Use and IBD, Cannabinoid Receptor System and Immune Regulation, Ulcerative Colitis Background, Ulcerative Colitis Subtypes, Goal of Ulcerative Colitis Treatment, Ulcerative Colitis Market, Trials, Financials)

- Mettrum Health Corp (Company Overview, Medical Marijuana, Facilities, Production, Bowmanville Facility, Creemore Facility, Monetizing Product Through Bowmanville, 500 kg License, Licensing No Longer A Constraint, Resuming Customer Acquisition, Market Strategy, RTO And Private Placement, Profits Could Reach C$50 Million, Barriers To Entry Growing, Oilseed Works Purchase, Financials)

- OrganiGram Holdings Inc. (Company Overview, Medical Marijuana, Facilities, Capacity, Products, Marketing, Patients, Trauma Healing Centers Agreement, Financials)

- Tweed Marijuana Inc.(Company Overview, Initial Financing, Medical Marijuana, Facilities, Smiths Falls Facility, Security, Growing Equipment, Laboratory, Expansion Plans, Smith Falls Grow Operations, Smiths Falls Capacity to Double, Mother Room Houses ~5,000 Plants, Smiths Falls Could Produce ~7,500 - 10,000 kg/Year, Tweed Farms, Tweed Farms Property, Tweed Farms Grow Operations, 70% Lower Costs, Capacity Estimated at ~2,900–3,700 kg Annually, Factors Offsetting Benefits of Greenhouse Production, Product Offerings, Pricing, Vaporizers, Radiation, Other Potential Revenue Streams, Sales and Marketing Strategy, Direct-to-Consumer Sales Process, Go-to-Market Strategy, Patient Acquisition, Medical Advisory Board, Canadian AIDS Society, Trade Events, Ownership, Financials)

1.) Lifetime Use of Marijuana by Country: 2007
2.) Types of Cannabinoids
3.) Potential Benefits of Cannabis Based on Research Studies
4.) Potential Adverse Effects of Marijuana
5.) DSM-IV-TR Cannabis Use and Induced Disorders
6.) Worldwide Number (Millions) and Prevalence (%) of Users by Type of Illicit Drug: 2012
7.) Comparison of Marijuana Laws in the Netherlands, Colorado State, Washington State, Uruguay
8.) World Cannabis Herb and Resin Production (Hectares, Metric Tons): 2003-2008
9.) Global Cannabis Production Volume (MT), Value (USD) and Average Selling Price (Million USD/MT): 2015-2020
10.) Global Cannabis Production Volume by Region (Metric Tons): 2015
11.) North America Cannabis Production Volume (MT), Value (USD) and Average Selling Price (Million USD/MT): 2015
12.) Global Sales of Over-the-Counter (OTC) Pharmaceuticals by Application (USD Million): 2013
13.) California Medical Marijuana Market Highlights
14.) Canada Licensed Producer Production by Company (kg): 2014-2018
15.) Therapeutic Uses Of Cannabis
16.) History of Canada Medical Marijuana Regulations: 1996-2014
17.) Key Differences Between MMAR and MMPR
18.) Sample MMPR Application Form
19.) Canada Medical Marijuana Market in 2024 Using Different Patient Number and Price Assumptions (Number, 2014 C$ /Gram)
20.) Canada Public LPs Expected Production Capacity (kg): 2015
21.) 15 Current Health Canada Licensed Producers (Location, Description, Capacity, Patients): 1Q 2015
22.) Aphria Product Offerings
23.) Bedrocan Operations Timeline: 2012-2015
24.) Bedrocan Cannabis Corp. Import Facility Features
25.) Bedrocan Cannabis Corp. Domestic Facility Features
26.) Bedrocan Cannabis Registration Application Form
27.) Bedrocan Cannabis Corp. Income Statement: 2015-2019
28.) Cannabis Science, Inc. Income Statement: 2012-2014
29.) Sativex Multiple Sclerosis Revenue Model : 2013-2027
30.) Sativex Cancer Pain Revenue Model: 2013-2027
31.) Tuberous Sclerosis Complex Case Studies Show Compelling CBD Benefits in Highly Refractory Epilepsy Patients
32.) Epidiolex Revenue Model: 2013-2028
33.) Published Research Citing the Clinical Potential of Cannabis in Inflammatory Bowel Disease
34.) Inflammatory Bowel Disease by Type, Endocannabinoid Changes and Receptor Changes
35.) The Five Types of UC: Variability in Acute Presentation and Long Term Outcomes
36.) GW Pharmaceutical Trials: 2014-2015
37.) GW Pharmaceuticals Income Statement (GBP Million): 2011-2017
38.) Mettrum Spectrum Products
39.) Mettrum Spectrum Use of Private Placement Proceeds
40.) Mettrum Health Corp. Income Statement: 2014-2019
41.) OrganiGram Current Product Offerings
42.) OrganiGram Future Product Offerings
43.) Smiths Falls Estimated Production Breakdown (kg)
44.) Tweed Farms Estimated Production Breakdown (kg)
45.) Factors Offsetting Benefits of Greenhouse Production
46.) Tweed Products and Prices
47.) Tweed Marijuana Inc. Income Statement: 2014-2016

1.) Indica and Sativa Cannabis Plants
2.) Global Pain Management Pharmaceuticals Revenue by Company (USD Billion, %): 2013
3.) Number of U.S. States Legalizing Medical Marijuana over Time: 1996-2014
4.) Patients by Classification Under Canada Marihuana Medical Access Regulations (Number, %): 2013
5.) 15 g and 5 g Containers with Product Type and CBD/THC Content by Weight %
6.) Canada Marihuana for Medical Purposes Regulations Patients and Growth Rate (Number, %): 2014-2034
7.) U.S. Medical Marijuana Population by State and Respective Penetration Rates (Number, %)
8.) Average Price Per Gram and Number of Strains for Selected LPs: 2014
9.) Number of Canada Physicians by Type and Province Prescribing Medical Marijuana: 2014
10.) Survey of Patients Using Medical Marijuana in Canada by Ailment: 2014
11.) Medical Marijuana Production Cycle by Time and Activity
12.) Long Run Average Cost of Cannabis Production (C$/Gram)
13.) THC Oil/Kif Butter/Medical Marijuana Infused Peanut Butter
14.) Public LP Enterprise Value Range: January 2015
15.) Bedrocan
16.) Bedropuur
17.) Bedica
18.) Bediol
19.) Bedrolite
20.) Canadian LP Pricing and Strain Offerings by Company (C$/Gram, Number Strains): 2014
21.) Ulcertative Colitis Schematic
22.) Aerial View of Tweed’s Smiths Falls Facility
23.) Smiths Falls Production Facility Layout
24.) Evolution of Smiths Falls’ Installed Capacity: 2014-2016
25.) Smiths Falls’ Mother Room and Cuttings
26.) Ariel View of Tweed Farms Production Facility
27.) Marijuana Vaporizers
28.) Selection of Tweed’s Strains Produced at Smiths Falls
Note: Product cover images may vary from those shown
3 of 3


4 of 3
- Aphria Inc
- Bedrocan Cannabis Corp.
- Cannabis Science, Inc.
- GW Pharmaceuticals plc
- Mettrum Health Corp
- OrganiGram Holdings Inc.
- Tweed Marijuana Inc.

Note: Product cover images may vary from those shown